BDR Pharma launches BDENZA oral solution for prostate cancer

BDR Pharmaceuticals has introduced BDENZA, an oral solution in 32mg/mL for the management of prostate cancer. BDENZA will be available at Rs 27,000 for 150mL. The company informed that the formulation offers lesser side effects in comparison to existing oral dosage forms of Enzalutamide.

Dr Aravind Badiger, Director, Technical Formulation, “Changing how we treat prostate cancer, BDENZA ORAL SOLUTION brings a mix of benefits to make things better for patients. It gives a strong 160mg dose in just one small 5ml serving, so there’s less hassle associated with lots of pills. Unlike fixed-dose tablets, doctors can adjust the dosage to fit each patient better. This oral solution is gentle on the stomach, avoiding issues like nausea. Plus, it is sugar-free and tastes good, making it easier for patients, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent”.

Raheel Shah, BDR Group Director (Business Development), said, “This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability.”